anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CD4 T cell help is essential to promote robust cytotoxic T cell responses and could be harnessed to improve outcomes of cancer immunotherapy. To induce CD4+ T cell responses, the inventors have developed artificial antigen presenting cells (AAPCs) that derived from a mouse fibroblast cell line genetically modified to express a single human leukocyte antigen class II molecule (HLA-DR), the human CD80 costimulation as well as CD54 and CD58 adhesion molecules and that constitutively express an antigen (Ag) in peptide or protein forms in different compartments involved in the major histocompatibility complex class II Ag presentation pathway. In particular, the inventors show that the AAPC expressing the Ag peptide in the endoplasmic reticulum (ER) or protein at the plasma membrane were more potent than Epstein-Barr virus (EBV)-transformed B cells to present epitopes to specific CD4+ T- cells. Interestingly, AAPC targeting the Ag peptide in the ER was more efficient than peptide-pulsed AAPC or autologous APC to amplify memory Ag-specific CD4+ T cells that harbor a Th1 profile and express granzyme B. So, the AAPC system is a reliable and standardized tool to generate a high number of Ag-specific CD4+ with effector functions useful for a cancer adoptive immunotherapy. Thus, the present invention relates to an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.
Methacetin Breath test (MBT) intervention. We will use the MBT test to measure time from administration of 13C methacetin to obtaining the peak elimination of 13CO2.
Peptides which exhibit improved broad spectrum antimicrobial activity are designed and synthesized based on the peptide sequences of magainin or PGS peptides. The modified peptide analogues are synthesized by replacing low helical potential amino acid residues with high helical potential residues and modifying the two termini in order to enhance the amphiphilic structures as well as to prolong antimicrobial activity by lowering their susceptibility to protease degradation. For example, low propensity residues within a strategic region of magainin II, e.g. Ser8, Gly13 and Gly18 are modified with Ala which is known to have high propensity. Amidation of Ser23, and acylation of Gly1 with acetyl or beta-alanyl and substitution of Gly1 with beta-alanine are carried out in order to lower the susceptibility to exopeptidase action. A D-Ala modification for disrupting a stretch of the helical structure is also prepared so as to demonstrate the importance of an amphiphilic helical structure for antimicrobial activity. The modified peptide analogues exhibit an increase of up to two orders of magnitude in antimicrobial activity and, in the most favorable case, no appreciable increase in hemolytic activity over magainin 1.
BACKGROUND: Health-related quality of life (HRQoL) is one of the most important outcome variables for assessing the effectiveness of intensive care, together with mortality and survival, where comorbidity is suggested to have high impact. However, studies are lacking that examine to what extent HRQoL is affected after a general ICU period, beyond that of the effects that may be claimed to be due to comorbidities.
DESIGN: Purpose-specific literature review including literature searches in PubMed, Cinahl, Scopus, and Cochrane library between 2010 and 2021.
MEASUREMENTS AND RESULTS: This Purpose-specific, i.e., task focused review examines HRQoL (assessed by either SF-36 or EQ-5D, > 30 days after leaving the hospital) in adult patients (≥ 18 years) having an ICU length of stay > 24 h. Further, the HRQoL comparisons were adjusted for age or comorbidity. A total of 11 publications were found. A majority comprised observational, prospective cohort studies, except three that were either case-control, cross-sectional comparison, or retrospective cohort studies. A total of 18,566 critically ill patients were included, and the response rate ranged from 16 to 94%. In all studies, a recurrent relevant finding was that HRQoL after ICU care was affected by pre-ICU comorbidities. In three studies (n = 3), which included a comorbidity adjusted control group, there were no effect of the critical care period itself on the registered HRQoL after the critical care period.
CONCLUSION: Health-Related Quality of Life (HRQoL) in former ICU patients appears to be primarily influenced by comorbidity. A notable limitation in this field of research is the high heterogeneity observed in the studies reviewed, particularly in terms of the HRQoL measurement tool employed, the duration of follow-up, the methodology for comorbidity assessment, and the adjustments for age and sex. Despite these variations and the limited number of studies in the review, the findings suggest a minimal HRQoL impact beyond the effects of comorbidity. Given the significant dearth of comprehensive studies in this domain, there is an escalating call for more thorough and detailed research endeavours.
Sixteen weeks of phone-based counselling at a rate of 1 session/week and ongoing access to a online platform (Nex J Connected Wellness) that has health promotion text and videos readily accessed in combination with text messaging exchanges between counselor and participant. Participants receive a Fitbit which is connected to the Nex J Connected Wellness such that counselors can monitor steps/day.
Facilitation taping was applied from the origins of the muscle to the insertion. Inhibition taping was applied from the insertio of the muscle to the origin. Facilitation taping and inhibition taping was applied on the target tissue with 25% tension. Y-band was used during facilitation taping and inhibition taping. It was applied to individuals with shoulder mild abduction, external rotation, elbow extension and supination position. Placebo taping was applied while in a resting position. In placebo taping, it was applied using two I bands in horizontal direction. In placebo taping, no tension was applied to the tapes. Evaluations were made while the subjects were standing. The biceps curl exercise position starts with the palms facing the trunk. Elbow flexion is completed by making full range of motion. The cases were randomized into 3 groups: group-1 facilitation taping, group-2 inhibition taping and group-3 placebo taping.The treatment sequence to be applied to the patients was determined by randomization. Facilitation, inhibition and placebo banding were applied to the patients, respectively. Accordingly, inhibition and placebo taping was applied to the cases that started with the facilitation taping. Placebo and facilitation banding were applied to the patients that started with inhibition banding, respectively. Facilitation and inhibition banding was applied to the cases that started with placebo banding, respectively. During the evaluation, banding application was kept by wearing plenty of clothes. Evaluators and subjects participating in the study did not have knowledge and experience about the taping method.
Administer Verapamil Hydrochloride Extended-release Capsules (PM) once daily at bedtime. Clinical trials studied doses of 100 mg, 200 mg, 300 mg, and 400 mg. The usual daily dose of extended-release Verapamil Hydrochloride Extended-release Capsules (PM) in clinical trials has been 200 mg given by mouth once daily at bedtime. In rare instances, initial doses of 100 mg a day may be warranted in patients who have an increased response to verapamil [e.g. patients with impaired renal function, impaired hepatic function, elderly, low-weight patients, etc. ( see Use in Specific Populations ( 8.5, 8.6, 8.7) )]. Base upward titration on therapeutic efficacy and safety evaluated approximately 24 hours after dosing. The antihypertensive effects of Verapamil Hydrochloride Extended-release Capsules (PM) are evident within the first week of therapy. 

If an adequate response is not obtained with 200 mg of Verapamil Hydrochloride Extended-release Capsules (PM), the dose may be titrated upward in the following manner:

a) 300 mg each evening b) 400 mg each evening (2 × 200 mg)

When Verapamil Hydrochloride Extended-release Capsules (PM) is administered at bedtime, office evaluation of blood pressure during morning and early afternoon hours is essentially a measure of peak effect. The usual evaluation of trough effect, which sometimes might be needed to evaluate the appropriateness of any given dose of Verapamil Hydrochloride Extended-release Capsules (PM), would be just prior to bedtime.
During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
Participants will be enrolled to receive Zuranolone orally, during the daytime on Day 1 and in the evening on Days 2 to 14. The first 10 enrolled participants will receive 50 mg (participants with a body weight of 54 kg or greater) or 40 mg (participants with a body weight less than 54 kg) once daily. The remaining participants will receive 40 mg once daily with the opportunity to down titrate to 30 mg if 40 mg is not tolerated.
U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
Risk Summary

There are no data on the presence of tapentadol in human milk, the effects on the breastfed infant, or the effects on milk production. Tapentadol is present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Infants exposed to NUCYNTA tablets through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NUCYNTA tablets and any potential adverse effects on the breastfed infant from NUCYNTA tablets or from the underlying maternal condition.
PCT No. PCT/HU88/00044 Sec. 371 Date Feb. 17, 1989 Sec. 102(e) Date Feb. 17, 1989 PCT Filed Jun. 22, 1988 PCT Pub. No. WO88/10111 PCT Pub. Date Dec. 29, 1988.The invention relates to a multilayer pharmaceutical formulation containing layers with various active ingredient content, a water-impermeable layer applied thereon and an adhesive layer ensuring the fixation to the body surface of the pharmaceutical formulation, which comprises: a silicone rubber layer directly contacting with the skin surface and ensuring the zero order kinetics of the dissolution of the active ingredient; as well as a multilaminated silicone rubber matrix comprising one or more layers(s) with various active ingredient content.
Azoospermia (no sperm in ejaculated semen) impacts 1% of men in the general population and 15% of infertile men, which translates to 645,000 males between the ages of 20 and 50 (prime reproductive years) in the United States. Spermatogenesis arises from a population of spermatogonial stem cells in the testes that maintain continuous sperm production throughout a man's post-pubertal life. Diseases or medical treatments that compromise the stem cell pool and/or prevent the stem cells from differentiating can cause infertility. Adult men have the option to cryopreserve a semen sample prior to therapy but this is not an option for prepubertal patients who are not yet producing sperm. This study will test the safety and feasibility of two approaches to restore sperm production using previously cryopreserved testicular tissues, which contain spermatogonial stem cells.

The first approach is autologous transplantation of testicular cells, including spermatogonial stem cells, into the testis using ultrasound-guided rete testis injection. The second approach is autologous grafting of intact pieces of testicular tissue under the skin in the scrotum.
FIELD: medicine. SUBSTANCE: short-time medicinal starvation is carried out, 3-5 days being starvation itself, 3 days being recovery period. 0.02% solution of sodium hydrochloride is injected intravenously by drops (its quantity being 200-400 ml) after starvation course. The process is carried out 3 times in 1-2 days. Thus stable decreasing in weight together with normalization of lipid and hydrocarbon exchanges are attained. EFFECT: decreases treatment time, increases efficiency of the method. 4 tbl
PURPOSE: Joint destruction is a major burden and an unsolved problem in rheumatoid arthritis (RA) patients. We designed an intra-articular mesoporous silica nanosystem (MSN-TP@PDA-GlcN) with anti-inflammatory and joint protection effects. The nanosystem was synthesized by encapsulating triptolide (TP) in mesoporous silica nanoparticles and coating it with pH-sensitive polydopamine (PDA) and glucosamine (GlcN) grafting on the PDA. The nano-drug delivery system with anti-inflammatory and joint protection effects should have good potency against RA.
METHODS: A template method was used to synthesize mesoporous silica (MSN). MSN-TP@PDA-GlcN was synthesized via MSN loading with TP, coating with PDA and grafting of GlcN on PDA. The drug release behavior was tested. A cellular inflammatory model and a rat RA model were used to evaluate the effects on RA. In vivo imaging and microdialysis (MD) system were used to analyze the sustained release and pharmacokinetics in RA rats.
RESULTS: TMSN-TP@PDA-GlcN was stable, had good biocompatibility, and exhibited sustained release of drugs in acidic environments. It had excellent anti-inflammatory effects in vitro and in vivo. It also effectively repaired joint destruction in vivo without causing any tissue toxicity. In vivo imaging and pharmacokinetics experiments showed that the nanosystem prolonged the residence time, lowered the Cmax value and enhanced the relative bioavailability of TP.
CONCLUSIONS: These results demonstrated that MSN-TP@PDA-GlcN sustained the release of drugs in inflammatory joints and produced effective anti-inflammatory and joint protection effects on RA. This study provides a new strategy for the treatment of RA.
The present invention relates to an image processing apparatus and a related method. The image processing device (10) comprises a data input (11) for receiving spectral computed tomography volumetric image data organized in voxels. The image data comprises a contrast enhanced volumetric image of a heart region in the subject's body and a reference volumetric image of the heart region, e.g. a virtual non-contrast image, wherein the contrast enhanced volumetric image conveys anatomical information about the coronary anatomy of the subject. The apparatus comprises a flow simulator (12) for: a three-dimensional coronary arterial tree model is generated based on the volumetric image data or a three-dimensional coronary arterial tree model based on the volumetric image data is received as input and a coronary arterial flow is simulated based on the three-dimensional coronary arterial tree model. The apparatus comprises a perfusion synthesis unit (13) for generating a perfusion image representing a blood distribution in the tissue at least one moment in time taking into account at least the reference volume image and the coronary flow simulation.
There have been postmarketing reports of angioedema in patients during initial and chronic treatment with pregabalin. Specific symptoms included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There were reports of life-threatening angioedema with respiratory compromise requiring emergency treatment. Discontinue pregabalin immediately in patients with these symptoms.

Exercise caution when prescribing Pregabalin capsules to patients who have had a previous episode of angioedema. In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema.
Patients with nasal defects from cancer, trauma, prior surgery, or birth often require complex reconstruction. Current techniques involve hand sketched skin templates and/or hand carved cartilage grafts that are formed intraoperatively for nasal reconstruction. This process is time consuming, heavily depends on the surgeon's skill, cannot be standardized, and is difficult to visualize with patients preoperatively. To overcome these barriers and shift surgical paradigms, we will use a regenerative medicine approach to nasal reconstruction to create patient specific and individualized results. We will leverage regenerative medicine techniques of 3D surface mapping, 3D printing and modeling, and new tissue preparation techniques for skin template creation and sculpting of cartilage grafting. Clinically this will improve patient specific outcomes, increase reproducibility, reduce operative times, and allow for an individualized approach to nasal reconstruction. This will be achieved by (1) establishing ideal diced cartilage graft parameters in the laboratory setting for moldable cartilage graft formation. This knowledge will be applied to (2) create diced cartilage grafts for nasal dorsum and tip reconstruction from 3D printed nasal molds. For nasal skin reconstruction, (3) 3D facial scans of patients' preoperatively will be used to generate patient specific templates for skin reconstruction. Ultimately, (4) these regenerative medicine techniques of cartilage and skin reconstruction performed with 3D planning can be shared in an interactive format with patients preoperatively. This will allow patients to be involved in the surgical planning of their nasal reconstruction to increase their autonomy and the individualization of their surgery.
Flavouring substances or odorants are transferred by contacting them with, or impregnating a fine porous layer of metal oxide produced by electrolytic means, the support layer is then contacted with a receptive medium to release the substances or the layer is stored with the receptive medium. The support itself is also claimed. The support is used for flavouring or adonising such things as foodstuffs, tea coffee, tobacco, milk products etc. and to either mask unpleasant smells or flavours or render an insipid smell more attractive. Previous supports such as paper release the flavourants in a non-uniform fashion, or supports which are sintered are heavy and large. Present support provides an easy means of releasing flavours in a uniform fashion without separation of the flavour components.
OBJECTIVE: This review sought to determine the characteristics of adults diagnosed with new onset laryngomalacia including airway symptoms, laryngoscopic findings, treatments, and outcomes. Moreover, we wanted to highlight suspected limitations in the literature.
DATA SOURCES: Studies were identified through CINAHL, Cochrane Review, PubMed, and Scopus published between 1966 and 2023.
REVIEW METHODS: The search was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis Extension for Scoping Reviews checklist by 2 independent investigators. A meta-analysis of proportions and continuous measures was conducted.
RESULTS: Of the 1121 abstracts identified, 33 articles pertaining to laryngomalacia in the adult population were included. The most common presenting symptoms were stridor at rest (78.3%, 65.1-88.3) and dyspnea with exertion (83.8%, 64.8-96.3). The most suspected etiology was exercise-induced (86.0%, 69.4-95.5), and the most common description of laryngomalacia on visualization was collapse of supraglottic structures during exercise (93.3%, 79.0-99.1). Nonsurgical options were attempted in 87.0% (54.0-99.1), which included oral appliances, respiratory retraining, breathing techniques, and working with a speech pathologist. Surgical options were ultimately performed in 84.2% (75.0-91.0). Complete resolution of symptoms following therapy was seen in 61.9% (48.0-74.6).
CONCLUSION: Adult onset laryngomalacia is difficult to characterize. It typically presents in patients during exercise, with neurological injury, or idiopathically. Surgical management can lead to improvement or complete resolution of symptoms. The need for a universal nomenclature is highlighted in this review, as it is inconsistently classified.
Despite significantly improved clinical outcomes in EGFR-mutant lung adenocarcinoma, all patients develop acquired resistance and malignancy on the treatment of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Understanding the resistance mechanisms is crucial to uncover novel therapeutic targets to improve the efficacy of EGFR-TKI treatment. Here, integrated analysis using RNA-Seq and shRNAs metabolic screening reveals glutathione S-transferase omega 1 (GSTO1) as one of the key metabolic enzymes that is required for EGFR-TKIs resistance in lung adenocarcinoma cells. Aberrant upregulation of GSTO1 confers EGFR-TKIs resistance and tumor metastasis in vitro and in vivo dependent on its active-site cysteine 32 (C32). Pharmacological inhibition or knockdown of GSTO1 restores sensitivity to EGFR-TKIs and synergistically enhances tumoricidal effects. Importantly, nucleophosmin 1 (NPM1) cysteine 104 is deglutathionylated by GSTO1 through its active C32 site, which leads to activation of the AKT/NF-κB signaling pathway. In addition, clinical data illustrates that GSTO1 level is positively correlated with NPM1 level, NF-κB-mediated transcriptions and progression of human lung adenocarcinoma. Overall, our study highlights a novel mechanism of GSTO1 mediating EGFR-TKIs resistance and malignant progression via protein deglutathionylation, and GSTO1/NPM1/AKT/NF-κB axis as a potential therapeutic vulnerability in lung adenocarcinoma.